Scientists have identified a bacterial protein fragment called corisin as a driver of pulmonary fibrosis, a progressive lung-scarring disease that can severely limit breathing and quality of life. In a new study reported by researchers at the University of Illinois Urbana-Champaign and Mie University in Japan, corisin was shown to infiltrate and disrupt the cell’s quality-control system, while blocking it with an antibody reduced the damage.
How the study points to a new disease mechanism
The research suggests that corisin is more than a marker associated with fibrosis. According to the study team, the fragment is biologically active and capable of directly injuring lung cells. When the investigators removed corisin from patient fluid samples using an antibody they developed, the fluid lost its lethal effect when applied to healthy cell cultures.
That finding matters because pulmonary fibrosis remains difficult to treat, and the discovery of a specific bacterial factor involved in the disease process could help researchers better understand how lung injury progresses. The study authors say the work moves corisin toward being a mechanistically defined and causally supported driver of disease, as well as a possible therapeutic target.
A potential route toward future treatments
The researchers also reported that neutralizing corisin with the antibody they created largely protected cells from injury. While the findings are still early, they offer a new direction for therapy development in a condition where preventing ongoing tissue damage is a major goal. The study was published in Nature Communications.
Pulmonary fibrosis often develops as lung tissue becomes progressively stiff and scarred, making oxygen exchange harder over time. By identifying a bacterial protein fragment that appears to contribute directly to that process, the study adds a new layer to the growing understanding of how infections, inflammation and tissue injury may intersect in chronic lung disease.
For now, the work remains preclinical, and further research will be needed to determine whether corisin-targeted strategies can help patients. Still, the results highlight a possible new biomolecular target in one of respiratory medicine’s most challenging diseases.
Photo source: AI-generated or edited image
